Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Formerly About Advanced Micro Devices -- Ignore unavailable to you. Want to Upgrade?

To: maceng2 who wrote (1427304)	12/4/2023 5:15:51 PM
From: golfer72	1 Recommendation Recommended By maceng2 Respond to of 1574589

Especially since "Covid" itself was easily treatable and a vaccine was not needed even if it worked and was safe

To: maceng2 who wrote (1427304)	12/4/2023 6:10:10 PM
From: Land Shark	2 Recommendations Recommended By Eric pocotrader Read Replies (2) \| Respond to of 1574589

No way is it anywhere close to that chump, for instance: Anaphylaxis after COVID-19 vaccination is rare. It has occurred at a rate of approximately 5 cases per one million vaccine doses administered. People receiving COVID-19 vaccines are less likely to die from COVID-19 and its complications and are at no greater risk of death from non-COVID causes, than unvaccinated people. Thrombosis with thrombocytopenia syndrome (TTS) has been rarely observed after J&J/Janssen COVID-19 vaccination ONLY and has occurred in approximately 4 cases per one million doses administered. TTS is a rare but serious adverse event that causes blood clots in large blood vessels and low platelets (blood cells that help form clots). READ a credible source, not from some crackpot lone wolf quack. cdc.gov